The addition of zolbetuximab to CAPOX led to a statistically significant improvement in progression-free survival and overall survival compared with placebo plus CAPOX for patients with Claudin-18.2–positive/HER2-negative, unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
A focused discussion on combination strategies with immune checkpoint inhibitors in patients with metastatic colorectal cancer.
Switching their focus to immune checkpoint inhibitors, panelists provide an overview on the role of immunotherapy in metastatic colorectal cancer.
Before closing out their discussion on BRAF-mutated metastatic colorectal cancer, panelists consider other novel combination strategies in this setting.
Shared insight on the BREAKWATER trial, which combined encorafenib, cetuximab, and chemotherapy in patients with BRAF V600E–mutated metastatic colorectal cancer.
Anna C. Pavlick, DO, discusses the phase 2 IGNYTE trial examining vusolimogene oderparepvec in combination with nivolumab in 3 tumor-specific cohorts, including 1 featuring patients with anti–PD-1–failed cutaneous melanoma.
Expert perspectives on the BEACON CRC trial, which combined encorafenib, cetuximab, and binimetinib in patients with BRAF V600E–mutated metastatic colorectal cancer.
Following its discussion on trastuzumab deruxtecan and tucatinib therapy in HER2+ mCRC, the panel emphasizes the importance HER2 status identification in metastatic colorectal cancer.
Neil H. Bander, MD, discusses preliminary results from a phase 1/2 study of pembrolizumab in combination with an androgen-receptor signaling inhibitor and alpha-PSMA-targeted radionuclide therapy in mCRPC.
Anna C. Pavlick, DO, discusses how ongoing research efforts at Weill Cornell Medicine are attempting to ameliorate unmet needs in melanoma.
Switching their focus to tucatinib, expert panelists review data from the MOUNTAINEER study and define the role of tucatinib in managing HER2+ metastatic colorectal cancer.
Comprehensive insight on the adverse event profile of antibody drug conjugate therapy as it compares to other agents in HER2+ metastatic colorectal cancer management.
Centering discussion on clinical trials and experience with trastuzumab deruxtecan, expert oncologists identify its value in the HER2+ treatment landscape.
After a brief overview on first-line treatment options for patients with metastatic colorectal cancer, panelists highlight the role HER2 status plays in the selection of novel therapies.
A comprehensive discussion on the barriers to molecular testing in metastatic colorectal cancer, along with challenges in utilizing these tests in the real-world setting.
Panelists consider the potential role for circulating tumor DNA to inform the selection of therapy for patients with metastatic colorectal cancer.
Massimo Cristofanilli, MD, and Sara Tolaney, MD, MPH, offer closing remarks on the HR+ breast cancer treatment landscape, offer advice for community oncologists, and look to the future.
Experts in metastatic colorectal cancer management highlight the role of molecular testing and testing modalities available in the academic and community settings.
A detailed look at treatment options for patients with metastatic HR+ breast cancer who have progressed on CDK4/6 inhibitors.
Experts in oncology consider when surgery is appropriate for patients with breast cancer.
Anna C. Pavlick, DO, discusses the potential benefit of neoadjuvant immunotherapy prior to surgical resection, according to results from the phase 2 SWOG S1801 trial.
Anna Pavlick, DO, MBA, discusses key updates from clinical trials that continue to shape the treatment of patients with melanoma, the role of immunotherapy in the frontline setting, and the importance of toxicity management and patient support.
Anna C. Pavlick, DO, discusses the sequencing of immunotherapy vs targeted therapy in BRAF-mutated melanoma.
Adjuvant nivolumab produced survival benefits in patients with resected stage IIIA melanoma, where a significant portion of patients were recurrence free at a median follow-up of over 20 months.
Drs Giaccone and He discuss the implications of their thymic cancer research, the importance of combining immunotherapy and anti-angiogenesis agents to treat solid tumors, and the challenges of investigating rare cancers.
Recent developments in cancers of the thymus, a small organ located in the mediastinum above the heart, have shined a light on a malignancy that only affects about 400 Americans annually.
The past decade has seen a change in the tide for patients with bladder cancer with the introduction of checkpoint blockade and molecular profiling.
Massimo Cristofanilli, MD, discusses the variety of targeted therapies available in metastatic hormone receptor–positive breast cancer.
Selina M. Luger, MD, FRCPC, Gail J. Roboz, MD, and Wendy Stock, MD, discuss how being female affected their careers and share the scientific achievements they most want to be remembered for in the leukemia field.
Selina M. Luger, MD, FRCPC; Gail J. Roboz, MD; and Wendy Stock, MD, discuss how they turned their leukemia career “lemons” into “lemonade.”
